Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This study is an extension study to the Callisto protocol CP-106. Subjects must have
completed all 12 treatment cycles of CP-106 without disease progression as per RECIST
criteria,to be eligible to to be enrolled in this study. This study will evaluate the safety
and efficacy of atiprimod treatment in patients with low to intermediate grade neuroendocrine
carcinoma who have metastatic or unresectable local-regional cancer and who have either
symptoms (diarrhea, flushing and/or wheezing) despite standard therapy (octreotide) or
progression of neuroendocrine tumor(s).